SCHEMBL279741

SCHEMBL279741

Cc1ccc(C(=O)CS(=O)(=O)c2ccncc2)s1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 4/20 0.49
NPC1 O15118 4/20 0.43
RAB9A P51151 3/20 0.43
DAO P14920 1/20 0.42
RECQL P46063 1/20 0.40
ALDH1A1 P00352 3/20 0.39
POLB P06746 2/20 0.39
HPGD P15428 1/20 0.39
CASP3 P42574 1/20 0.39
SENP8 Q96LD8 1/20 0.39
SENP7 Q9BQF6 1/20 0.39
SENP6 Q9GZR1 1/20 0.39
KMT2A Q03164 3/20 0.38
TDP1 Q9NUW8 1/20 0.38
MAPT P10636 1/20 0.38
MEN1 O00255 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
LMNA P02545 1/20 0.37
NAMPT P43490 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL280382 0.84 HSD11B1 (0.45) HSD11B1NPC1RAB9ADAORECQL
SCHEMBL279755 0.76 HSD11B1 (0.40) HSD11B1NPC1RAB9ADAOALDH1A1
SCHEMBL279925 0.74 KMT2A (0.45) HSD11B1NPC1RAB9ADAORECQL
SCHEMBL280137 0.73 ADORA2A (0.44) NPC1RAB9ADAOALDH1A1POLB
SCHEMBL280361 0.72 RAB9A (0.47) NPC1RAB9ADAOALDH1A1POLB
SCHEMBL280366 0.72 RAB9A (0.44) NPC1RAB9ADAOALDH1A1POLB
SCHEMBL13060968 0.72 RAB9A (0.50) NPC1RAB9ADAORECQLALDH1A1
SCHEMBL280130 0.71 NPC1 (0.44) NPC1RAB9ADAOALDH1A1POLB
SCHEMBL279931 0.71 RAB9A (0.43) NPC1RAB9ADAOALDH1A1POLB
SCHEMBL280369 0.71 HTT (0.49) HSD11B1NPC1RECQLALDH1A1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-8134013-B2 Amide compound and thrombopoietin receptor activator NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2012-03-13 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR NISSAN CHEMICAL INDUSTRIES, LTD. (JP) 2009-05-21 US disclosed
EP-1845090-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR Nissan Chemical Industries, Ltd. (JP) 2007-10-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090131659-A1 AMIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR TEK, PTAFR, MPL HSD11B1 3197/4885NPC1 3107/4885RAB9A 2458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.